Rudy Patrick , Parag Mahale , Bradley K. Ackerson , Vennis Hong , Sally Shaw , Banshri Kapadia , Brigitte Spence , Matt Feaster , Jeff Slezak , Julie A. Stern , Gregg S. Davis , Gabriella Goodwin , Bruno Lewin , Joseph A. Lewnard , Hung Fu Tseng , Sara Y. Tartof
{"title":"Respiratory syncytial virus vaccine uptake among adults aged ≥60 years in a large, integrated healthcare system in Southern California 2023–2024","authors":"Rudy Patrick , Parag Mahale , Bradley K. Ackerson , Vennis Hong , Sally Shaw , Banshri Kapadia , Brigitte Spence , Matt Feaster , Jeff Slezak , Julie A. Stern , Gregg S. Davis , Gabriella Goodwin , Bruno Lewin , Joseph A. Lewnard , Hung Fu Tseng , Sara Y. Tartof","doi":"10.1016/j.vaccine.2025.127033","DOIUrl":null,"url":null,"abstract":"<div><div>During the 2023–2024 respiratory syncytial virus (RSV) season, vaccination was recommended for adults ≥60 years based on shared clinical decision-making with their healthcare providers. We examined RSV vaccine uptake and characteristics associated with uptake among age-eligible Kaiser Permanente Southern California (KPSC) patients. Our study cohort included all patients ≥60 years from September 23, 2023 (i.e., date RSV vaccination first became available at KPSC; <em>N</em> = 1,003,132) to April 9, 2024 (i.e., end of local RSV season). To identify sociodemographic and clinical characteristics associated with RSV vaccination, we used multivariable robust Poisson regression to estimate the adjusted relative risk (aRR) and 95 % CI. Overall, 7.6 % of patients were vaccinated for RSV. In multivariable regression analyses, those aged 70–79.9 years (aRR: 1.36; 95 % CI: 1.34–1.39) and aged ≥80 years (aRR: 1.35; 95 % CI: 1.32–1.38) were more likely to be vaccinated, compared with those aged 60–69.9 years. Compared with Non-Hispanic White patients, Asian (aRR: 0.95; 95 % CI: 0.93–0.97), Hispanic (aRR: 0.52; 95 % CI: 0.51–0.54), Non-Hispanic Black (aRR: 0.69; 95 % CI: 0.67–0.71), Pacific Islander (aRR: 0.91; 95 % CI: 0.84–0.98), and Native American or Alaska Native (aRR: 0.80; 95 % CI: 0.70–0.92) patients were less likely to be vaccinated. Those in higher neighborhood deprivation quartiles were less likely to be vaccinated (Q2: aRR: 0.86; 95 % CI: 0.85–0.88; Q3: aRR: 0.77; 95 % CI: 0.76–0.79; and Q4: aRR: 0.67; 95 % CI: 0.65–0.68), compared with those in the lowest deprivation quartile. We found low vaccination uptake and identified disparities in vaccination that might exacerbate existing disparities in RSV infection and severe RSV disease among certain populations. CDC's ACIP recently updated their recommendations for all adults 75+ years, and this might begin to address these disparities.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127033"},"PeriodicalIF":4.5000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25003305","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Respiratory syncytial virus vaccine uptake among adults aged ≥60 years in a large, integrated healthcare system in Southern California 2023–2024
During the 2023–2024 respiratory syncytial virus (RSV) season, vaccination was recommended for adults ≥60 years based on shared clinical decision-making with their healthcare providers. We examined RSV vaccine uptake and characteristics associated with uptake among age-eligible Kaiser Permanente Southern California (KPSC) patients. Our study cohort included all patients ≥60 years from September 23, 2023 (i.e., date RSV vaccination first became available at KPSC; N = 1,003,132) to April 9, 2024 (i.e., end of local RSV season). To identify sociodemographic and clinical characteristics associated with RSV vaccination, we used multivariable robust Poisson regression to estimate the adjusted relative risk (aRR) and 95 % CI. Overall, 7.6 % of patients were vaccinated for RSV. In multivariable regression analyses, those aged 70–79.9 years (aRR: 1.36; 95 % CI: 1.34–1.39) and aged ≥80 years (aRR: 1.35; 95 % CI: 1.32–1.38) were more likely to be vaccinated, compared with those aged 60–69.9 years. Compared with Non-Hispanic White patients, Asian (aRR: 0.95; 95 % CI: 0.93–0.97), Hispanic (aRR: 0.52; 95 % CI: 0.51–0.54), Non-Hispanic Black (aRR: 0.69; 95 % CI: 0.67–0.71), Pacific Islander (aRR: 0.91; 95 % CI: 0.84–0.98), and Native American or Alaska Native (aRR: 0.80; 95 % CI: 0.70–0.92) patients were less likely to be vaccinated. Those in higher neighborhood deprivation quartiles were less likely to be vaccinated (Q2: aRR: 0.86; 95 % CI: 0.85–0.88; Q3: aRR: 0.77; 95 % CI: 0.76–0.79; and Q4: aRR: 0.67; 95 % CI: 0.65–0.68), compared with those in the lowest deprivation quartile. We found low vaccination uptake and identified disparities in vaccination that might exacerbate existing disparities in RSV infection and severe RSV disease among certain populations. CDC's ACIP recently updated their recommendations for all adults 75+ years, and this might begin to address these disparities.
期刊介绍:
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.